Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
National Taiwan University Hospital |
---|---|
Information provided by: | National Taiwan University Hospital |
ClinicalTrials.gov Identifier: | NCT00173290 |
In this study proposal, the investigators will extend their previous studies and examine the kinetic cytotoxic activity with concordant expression of inhibitory natural killer (NK) receptors (iNKR) on activated T cells. The inhibitory role of cytokines will be defined by utilizing the investigators' previously established models of mixed lymphocytes and tumor cells coculture to analyze the expression and activity of cytokines involved in the regulation of iNKRs on cancer-encountered T cells.
Condition |
---|
Cervical Cancer Breast Cancer Endometrial Cancer Cancer |
Study Type: | Observational |
Estimated Enrollment: | 200 |
Study Start Date: | July 2004 |
Estimated Study Completion Date: | December 2006 |
In our extended studies, we have directly examined the expressions of various inhibitory natural killer cell Receptors (iNKRs) on Tumor-infiltrating lymphocytes (TILs) derived from human Cervical cancer (CC) by triple-color flow cytometry with combination of different surface markers. We found up-regulated expression of certain iNKRs (CD94/NKG2A) in TILs and in mixed lymphocyte-cancer cell cocultures. In our previous studies, we demonstrated that certain cytokines, including IL-10, TGF-beta (Sheu et al, Journal of Immunology, 2001, 167:2972-2978), and IL-15 (Sheu et al, Cancer Research, 2005, 65:2921-2929) can be expressed by CC cells. We further demonstrated that activated T cells bear iNKRs which inhibit cytotoxic activity. iNKRs are proposed to restrain the T cell receptor (TCR)-mediated cytolysis. We found that CC cells had altered HLA-A, -B, and -C molecules in a cancer microenvironment. The acquisition of both NK-like activity and expression of iNKRs by these T cells is parallel to prevent damage to normal host cells.
However, there is also limited knowledge about the regulatory role of iNKR expression in T cell cytotoxicity.
Ages Eligible for Study: | 18 Years to 50 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contact: Bor-Ching Sheu, MD, PhD | 886-2-2312-3456 ext 5559 | bcsheu@ha.mc.ntu.edu.tw |
Taiwan | |
National Taiwan University Hospital | Recruiting |
Taipei, Taiwan, 100 | |
Contact: Bor-Ching Sheu, MD, PhD 886-2-2312-3456 ext 5559 bcsheu@ha.mc.ntu.edu.tw |
Principal Investigator: | Bor-Ching Sheu, MD, PhD | Department of Obstetrics and Gynecology, National Taiwan University Hospital |
Study ID Numbers: | 9461700613, NTUH 94-S045, NTUH 95-0399, NTUCM-9406, NSC93-2314-B002-065, NSC93-2314-B002-164 |
Study First Received: | September 12, 2005 |
Last Updated: | June 2, 2008 |
ClinicalTrials.gov Identifier: | NCT00173290 History of Changes |
Health Authority: | Taiwan: Department of Health |
Cervical cancer Breast cancer T lymphocyte NK receptor |
Genital Diseases, Female Endometrial Neoplasms Skin Diseases Genital Neoplasms, Female Uterine Diseases |
Uterine Neoplasms Breast Neoplasms Endometrial Cancer Urogenital Neoplasms Breast Diseases |
Genital Diseases, Female Neoplasms Endometrial Neoplasms Neoplasms by Site Skin Diseases Genital Neoplasms, Female |
Uterine Diseases Uterine Neoplasms Breast Neoplasms Urogenital Neoplasms Breast Diseases |